Hospital and Internal Medicine Podcast

27 Jan 2022 09:23

Heart Failure with Preserved Ejection Fraction (Diastolic CHF) and SGLT-2 Inhibitor Therapy

The double-blind, randomized phase III EMPEROR-Preserved trial showed a benefit of the sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF).

Now let us dig a bit more into those headlines.

Отзывы

Podcastly – the best platform for podcasters and podcast lovers. More than 10 millions of audio content that available on Android/iOS/Web/Desktop and Telegram.

Social networks

Select language

🇺🇸